BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...237. FDA accepts Aveo NDA FDA accepted an NDA from Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) for tivozanib...
BioCentury | Nov 5, 2019
Company News

Nov. 4 Company Quick Takes: FDA approves RedHill’s antibiotic; plus NiKang, Revolution-Amgen, Aveo and Tmunity-Oncora

...$0.57 Monday after disclosing that FDA recommended the company not submit an NDA for Fotivda tivozanib...
...homology protein tyrosine phosphatase 2 Elizabeth S. Eaton, Staff Writer Talicia (RHB-105, heliconda) AMG 510 Fotivda, tivozanib (ASP4130, AV-951, krn951) RedHill...
BioCentury | Apr 11, 2019
Company News

Aveo could lose Fotivda's EU approval if August analysis confirms negative OS trend

...EMA's CHMP will consider regulatory action should an interim overall survival analysis of Fotivda tivozanib, planned...
...OS trend that Aveo disclosed in an April 3 SEC filing. The European Commission approved Fotivda...
...FLT4) - Vascular endothelial growth factor receptor 3 Elizabeth S. Eaton, Staff Writer Fotivda, tivozanib (ASP4130, AV-951, krn951) Aveo...
BioCentury | Feb 1, 2019
Clinical News

Aveo shares drop with uncertainty of NDA submission for Fotivda

...to FDA based on preliminary survival data from the Phase III TIVO-3 trial for Fotivda tivozanib...
...six months despite reporting preliminary data from TIVO-3 showing no overall survival (OS) benefit for Fotivda...
...Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Product: Fotivda tivozanib Business: Cancer Sandi Wong Fotivda, tivozanib (ASP4130, AV-951, krn951) Aveo...
BioCentury | Jan 31, 2019
Company News

Aveo shares drop with uncertainty of NDA submission for Fotivda

...to FDA based on preliminary survival data from the Phase III TIVO-3 trial for Fotivda tivozanib...
...six months despite reporting preliminary data from TIVO-3 showing no overall survival (OS) benefit for Fotivda...
...receptor 2; VEGFR-3 (FLT4) - Vascular endothelial growth factor receptor 3 Sandi Wong Fotivda, tivozanib (ASP4130, AV-951, krn951) Aveo...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Submit NDA 1Q19 Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) / Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) Fotivda tivozanib...
BioCentury | Nov 9, 2018
Clinical News

Aveo RCC compound trends toward detrimental survival effect, again

...in about six months despite reporting preliminary data showing no overall survival benefit for Fotivda tivozanib...
...approval of Fotivda as first-line treatment of RCC based on data from TIVO-1 alone. While Fotivda...
...and safety Status: Phase III data Milestone: Submit NDA (5/2019) Elizabeth S. Eaton Fotivda, tivozanib (ASP4130, AV-951, krn951) Aveo...
BioCentury | Nov 6, 2018
Clinical News

Aveo RCC compound trends toward detrimental survival effect, again

...Tuesday after reporting preliminary data late Monday that showed no overall survival benefit for Fotivda tivozanib...
...approval of Fotivda as first-line treatment of RCC based on data from TIVO-1 alone. While Fotivda...
...and 3, is approved in Europe to treat advanced RCC. Elizabeth S. Eaton Fotivda, tivozanib (ASP4130, AV-951, krn951) Aveo...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Hakko Kirin Co. Ltd. (Tokyo:4151) / Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) / EUSA Pharma Ltd. Fotivda tivozanib...
BioCentury | Jul 20, 2018
Clinical News

Aveo drops on delay for Phase III tvozanib readout

...for at least the second time an expected readout from a Phase III trial of tivozanib...
...Tivozanib, an inhibitor of VEGF receptors 1, 2 and 3, is approved in Europe as Fotivda...
...and safety Status: Phase III ongoing Milestone: Phase III data (4Q18) Sandi Wong Fotivda, tivozanib (ASP4130, AV-951, krn951) Aveo...
Items per page:
1 - 10 of 156